-
Mashup Score: 0In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary - 2 month(s) ago
Just as Eli Lilly appeared to be gaining an edge over its metabolic medicine rival Novo Nordisk in the U.S. | Just as Eli Lilly appeared to be gaining an edge over its metabolic medicine rival Novo Nordisk in the U.S. obesity market, Novo has locked in a new formulary access deal that could give its star weight loss drug Wegovy a major advantage over its Lilly counterpart.
Source: www.fiercepharma.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Tariff hits to generic drugs could 'blow back on everybody' without supply chain resilience, says USP chief - 2 month(s) ago
While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily toward branded drugmakers, generic medicines and the companies that manuf | Generic drug makers will be uniquely vulnerable if the Trump administration rolls out pharmaceutical tariffs, thanks to just how “little resilience” the industry enjoys compared to its patented counterpart, CEO of the United States Pharmacopeia, Ronald Piervincenzi, said in an interview.
Source: www.fiercepharma.comCategories: General Medicine NewsTweet-
#Tariffs hits to #generics drugs could 'blow back on everybody' without supply chain resilience, says USP chief | #pharma https://t.co/3CT49eQh8X
-
-
Mashup Score: 2Sanofi, Regeneron score their 7th indication for Dupixent with FDA nod to treat hives condition - 2 month(s) ago
On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. | Sanofi and Regeneron have scored an FDA approval for Dupixent in its seventh indication—chronic spontaneous urticaria (CSU). The nod comes 18 months after the U.S. regulator rejected Dupixent in the same indication.
Source: www.fiercepharma.comCategories: General Medicine NewsTweet-
BREAKING: Sanofi/Regeneron scores their 7th indication for Dupixent with Chronic Urticaria (Hives) https://t.co/oeviOe7epd
-
-
Mashup Score: 0Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy - 5 month(s) ago
After a run of court victories in a five-year patent dispute with the U.S. | After a run of court victories in a patent dispute with the U.S. government, Gilead has agreed to settle to resolve the feds’ last-ditch appeal. Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis.
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet-
“The case surrounds a research collaboration between Gilead and the Centers for Disease Control and Prevention (CDC) two decades ago to discover whether Truvada—which was approved in 2004 to treat HIV—could also prevent the infection.” https://t.co/g1C7wrxTVR
-
-
Mashup Score: 0Wegovy and Zepbound tipped to fuel $20B boom in heart failure market - 6 month(s) ago
GlobalData has named heart failure as the n | GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade.
Source: www.fiercepharma.comCategories: General Medicine News, Future of MedicineTweet-
Wegovy and Zepbound tipped to fuel $20B boom in #heartfailure market | #GLP1 #weightloss https://t.co/8QRsTolrKi
-
-
Mashup Score: 5
In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory trials at least be underway at the time of these conditional nods. | In a draft guidance document, the FDA specified criteria to determine whether a confirmatory trial is “underway” prior to an accelerated approval.
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet-
RT @FiercePharma: FDA looks to clarify confirmatory trial mandate for accelerated approvals https://t.co/YGOetIsjGt
-
-
Mashup Score: 0Bavarian Nordic inks mpox vaccine pact with Serum Institute of India, expands global reach of the shot - 6 month(s) ago
As Bavarian Nordic works to increase global access to its mpox vaccine, the company has inked a manufacturing
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet-
“Once SII receives regulatory approvals, it may begin producing the mpox shot as a contract manufacturer for Bavarian Nordic (BN). The deal is designed to expand capacity and provide additional global access to the vaccine during outbreaks of the virus” https://t.co/6vJYe2bShQ
-
-
Mashup Score: 0
One of the keys to cutting the cost of drugs in the United States is to raise their cost in other countries, Eli Lilly CEO David Ricks said Tuesday in an
Source: www.fiercepharma.comCategories: General Medicine News, Future of MedicineTweet-
.@EliLillyandCo CEO Ricks provides hints on how #Trump will approach #healthcare issues https://t.co/KcUE64XrlO
-
-
Mashup Score: 0Amgen's Blincyto keeps 96% of pediatric leukemia patients alive and disease-free in 'practice changing' 3-year study - 7 month(s) ago
Ten years after its first FDA approval, Amgen’s Blincyto continues to make inroads in treating acute lymphoblastic leukemia. | Investigators halted study randomization early based on the strong showing of a 96% disease-free survival rate at the three-year mark, compared with solo chemotherapy’s 87.9%.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
.@Amgen's Blincyto keeps 96% of #pediatrics #leukemia patients alive and disease-free in 'practice changing' 3-year study | #cancer https://t.co/LAucuyP7kH
-
-
Mashup Score: 0For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access - 7 month(s) ago
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care Excellence (NICE) has laid out plans for an unprecedented phased rollout that | Roughly 220,000 people in England will be eligible for the drug during the three-year launch phase. Afterward, officials plan to open access to a wider group of obesity patients, which numbers in the millions in England.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
For first phase of #Mounjaro's #obesity rollout in #England, only a limited number of patients will have access | #UK #GLP1s #weightloss https://t.co/o0E0Rt29SU
-
In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary | #GLP1 #weightloss https://t.co/8SUg8wTfR3